Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12272001 | 0.83 | MAPK9 (0.40) | MAPK9MAPK10L3MBTL1GAAHTT | |
| SCHEMBL13323082 | 0.77 | KMT2A (0.39) | GAAHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL2237600 | 0.72 | — | — | |
| SCHEMBL10094582 | 0.70 | MAPK9 (0.43) | MAPK9MAPK10L3MBTL1GAAHTT | |
| SCHEMBL1914533 | 0.69 | L3MBTL1 (0.54) | MAPK9MAPK10L3MBTL1GAAHTT | |
| SCHEMBL4660326 | 0.69 | MAPK9 (0.39) | MAPK9MAPK10L3MBTL1GAAHTT | |
| SCHEMBL28304876 | 0.69 | MAPK9 (0.36) | MAPK9MAPK10L3MBTL1GAAHTT | |
| SCHEMBL28239177 | 0.69 | GAA (0.43) | MAPK9MAPK10L3MBTL1GAAHTT | |
| SCHEMBL31422607 | 0.69 | KMT2A (0.40) | GAAMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6792166 | 0.68 | L3MBTL1 (0.52) | MAPK9MAPK10L3MBTL1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673905-B2 | Imidazo pyrazines | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673905-B2 | Imidazo pyrazines | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120238564-A1 | IMIDAZO PYRAZINES | LUK KIN-CHUN (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238564-A1 | IMIDAZO PYRAZINES | LUK KIN-CHUN (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2011101640-A1 | FUSED HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF MALARIA | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101640-A1 | FUSED HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF MALARIA | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2011-08-25 | — | — | WO | disclosed |
| US-7709475-B2 | 5-[2-(cyclohexyloxy)-6-methyl-4-pyrimidinyl]-2-[5-(4-methyl-1-piperazinyl)methyl-2-pyrazinyl]amino-1,3-thiazole; anticarcinogenic agent; G1 phase in cell cycle; great selectivity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-04 | — | — | US | disclosed |
| US-7709475-B2 | 5-[2-(cyclohexyloxy)-6-methyl-4-pyrimidinyl]-2-[5-(4-methyl-1-piperazinyl)methyl-2-pyrazinyl]amino-1,3-thiazole; anticarcinogenic agent; G1 phase in cell cycle; great selectivity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-04 | — | — | US | disclosed |
| US-20080081811-A1 | Selective Inhibitors Against Cdk4 and Cdk6 Having Aminothiazole Skeleton | BANYU PHARMACEUTICAL CO., LTD (JP) | 2008-04-03 | — | — | US | disclosed |
| US-20080081811-A1 | Selective Inhibitors Against Cdk4 and Cdk6 Having Aminothiazole Skeleton | BANYU PHARMACEUTICAL CO., LTD (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-1754706-A1 | SELECTIVE INHIBITORS AGAINST Cdk4 AND Cdk6 HAVING AMINOTHIAZOLE SKELETON | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-21 | — | — | EP | disclosed |
| EP-1218376-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6586424-B2 | Anticancer agents; anticholesterol agents | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |
| US-6586423-B2 | 2-(Pyridin-2-ylamino)-thiazole-5-carbonitrile derivatives; angiogenesis inhibitors; antitumor and anticarcinogenic agents; atherosclerosis, macular degeneration, diabetic retinopathy | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |
| US-20030064996-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | disclosed |
| CN-1390215-A | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2003-01-08 | — | — | CN | disclosed |
| EP-1218376-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020147203-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2002-10-10 | — | — | US | disclosed |
| EP-1218376-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001017995-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147203-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | MAPK9 138/4885MAPK10 118/4885L3MBTL1 2910/4885 |
| US-20080081811-A1 | Selective Inhibitors Against Cdk4 and Cdk6 Having Aminothiazole Skeleton | CDK4, CDK6, CDK3 | MAPK9 256/4885MAPK10 212/4885L3MBTL1 1301/4885 |
| US-20030064996-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | MAPK9 138/4885MAPK10 118/4885L3MBTL1 2910/4885 |
| US-20120238564-A1 | IMIDAZO PYRAZINES | THPO, MCL1, IKZF3 | MAPK9 3583/4885MAPK10 3289/4885L3MBTL1 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.